Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer

Cancer Immunology, Immunotherapy

Volumn 66, Issue 8, 2017, Pages 969-977

  Chae, Chang Suk ^a   Teran Cabanillas, Eli ^a,b   Cubillos Ruiz, Juan R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSIDAD AUTÓNOMA DE SINALOA   (Mexico)

Author keywords

Dendritic cells; Immunosuppression; Immunotherapy; Ovarian cancer; Regulatory myeloid suppressor cells; Tumor microenvironment

Indexed keywords

CD40 ANTIGEN; DENDRITIC CELL VACCINE; NANOPARTICLE; TOLL LIKE RECEPTOR; CANCER VACCINE;

CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; GENE EDITING; HOST CELL; HUMAN; IMMUNOREGULATION; OVARY CANCER; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; FEMALE; IMMUNITY; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; MYELOID-DERIVED SUPPRESSOR CELL; OVARIAN NEOPLASMS; TUMOR ESCAPE;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNITY; IMMUNOMODULATION; IMMUNOTHERAPY; MYELOID-DERIVED SUPPRESSOR CELLS; OVARIAN NEOPLASMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85013124311     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-1958-2     Document Type: Review

References (56)

1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30
2. Matulonis UA et al (2016) Ovarian cancer. Nat Rev Dis Primers 2:16061
3. Giornelli GH (2016) Management of relapsed ovarian cancer: a review. SpringerPlus 5(1):1197
4. Zhang L et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203–213
5. Nesbeth Y et al (2009) CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res 69(15):6331–6338
6. Nesbeth YC et al (2010) CD4 + T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J Immunol 184(10):5654–5662
7. Conejo-Garcia JR et al (2004) Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 10(9):950–958
8. Barnett B et al (2005) Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54(6):369–377
9. Curiel TJ et al (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9(5):562–567
10. Huarte E et al (2008) Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 68(18):7684–7691
11. Cubillos-Ruiz JR et al (2009) Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 119(8):2231–2244
12. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264
13. Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205–214
14. Morgan RA et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126–129
15. Dudley ME et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850–854
16. Hamanishi J et al (2015) Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33(34):4015–4022
17. Kershaw MH et al (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1):6106–6115
18. Kandalaft LE et al (2013) Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2(1):e22664
19. Geissmann F et al (2010) Development of monocytes, macrophages, and dendritic cells. Science 327(5966):656–661
20. Mildner A, Jung S (2014) Development and function of dendritic cell subsets. Immunity 40(5):642–656
21. Takizawa H, Boettcher S, Manz MG (2012) Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood 119(13):2991–3002
22. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253–268
23. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182(8):4499–4506
24. Conejo-Garcia JR, Rutkowski MR, Cubillos-Ruiz JR (2016) State-of-the-art of regulatory dendritic cells in cancer. Pharmacol Ther 164:97–104
25. Scarlett UK et al (2009) In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 69(18):7329–7337
26. Scarlett UK et al (2012) Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 209(3):495–506
27. Munder M, Arginase (2009) an emerging key player in the mammalian immune system. Br J Pharmacol 158(3):638–651
28. Cubillos-Ruiz JR et al (2010) CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget 1(5):329–338
29. Liu HT, Gao P (2016) The roles of microRNAs related with progression and metastasis in human cancers. Tumor Biol 37(12):15383–15397. doi:10.1007/s13277-016-5436-9
30. Rodriguez A et al (2007) Requirement of bic/microRNA-155 for normal immune function. Science 316(5824):608–611
31. Cubillos-Ruiz JR et al (2012) Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res 72(7):1683–1693
32. Zonari E et al (2013) A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood 122(2):243–252
33. Tesone AJ et al (2016) Satb1 overexpression drives tumor-promoting activities in cancer-associated dendritic cells. Cell Rep 14(7):1774–1786
34. Cubillos-Ruiz JR et al (2015) ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161(7):1527–1538
35. Hetz C, Chevet E, Harding HP (2013) Targeting the unfolded protein response in disease. Nat Rev Drug Discov 12(9):703–719
36. Yoshida H et al (2001) XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107(7):881–891
37. Lee AH, Iwakoshi NN, Glimcher LH (2003) XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol 23(21):7448–7459
38. Tang CH et al (2014) Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. J Clin Invest 124(6):2585–2598
39. Chen X et al (2014) XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature 508(7494):103–107
40. Auf G et al (2010) Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad Sci USA 107(35):15553–15558
41. Dalton LE et al (2013) The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. Br J Cancer 108(6):1340–1347
42. Davies MP et al (2008) Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int J Cancer 123(1):85–88
43. Matsuo K et al (2013) The endoplasmic reticulum stress marker, glucose-regulated protein-78 (GRP78) in visceral adipocytes predicts endometrial cancer progression and patient survival. Gynecol Oncol 128(3):552–559
44. Herber DL et al (2010) Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 16(8):880–886
45. Condamine T et al (2016) Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol 1(2):aaf8943
46. Schoenberger SP et al (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature 393(6684):480–483
47. Bennett SR et al (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393(6684):478–480
48. Beatty GL et al (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024):1612–1616
49. Vonderheide RH et al (2013) CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother 62(5):949–954
50. Marigo I et al (2016) T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell 30(3):377–390
51. Beatty GL et al (2013) A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 19(22):6286–6295
52. Rosenfeld MR et al (2010) A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol 12(10):1071–1077
53. Hillaireau H, Couvreur P (2009) Nanocarriers’ entry into the cell: relevance to drug delivery. CMLS Cell Mol Life Sci 66(17):2873–2896
54. Cubillos-Ruiz JR, Fiering S, Conejo-Garcia JR (2009) Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future Oncol 5(8):1189–1192
55. Gaj T, Gersbach CA, Barbas CF 3rd (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31(7):397–405
56. Platt RJ et al (2014) CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159(2):440–455